BCL2 and neoplasm: Our results showed that by degrading multiple BET members, and by modulating the expression of Bcl-2 family members, BETd-260 triggered massive apoptosis in OS cells and in OS xenograft tumor tissue, and eventually led to profound and sustained inhibition of tumor growth in both OS cell-line-derived xenografts and patient-derived xenografts (PDX) models in mice.